AI-Powered registry to track Real-World use of prostate cancer drug
NCT ID NCT07484269
First seen Mar 21, 2026 · Last updated May 12, 2026 · Updated 9 times
Summary
This study will collect information from about 753 patients with metastatic prostate cancer who receive a drug called lutetium-177 vipivotide tetraxetan. The goal is to understand how the drug is used in everyday medical practice and what outcomes patients experience. No new treatments are given; the study simply observes and records data from routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.